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Abstract
Background: Cholera remains a serious public health problem in low-income countries despite efforts in the past to promote
oral rehydration therapy as major treatment. In 2007, the majority of worldwide cases (94%) and deaths (99%) were reported
from Africa. To improve cholera control efforts in addition to maintaining and improving existing water supply, sanitation and
hygiene behaviour measures, the World Health Organization has recently started to consider the use of vaccines as an additional
public health tool. To assess this new approach in endemic settings, a project was launched in Zanzibar to vaccinate 50,000
individuals living in communities at high risk of cholera with an oral two-dose vaccine (Dukoral®).
Immunisation programmes in low-income countries have suffered a reduced coverage or were even brought to a halt because
of an ignorance of local realities. To ensure the success of vaccination campaigns, implementers have to consider community-
held perceptions and behaviours regarding the infectious disease and the vaccine of interest.
The main aim of this study is to provide advice to the Ministry of Health and Social Welfare of Zanzibar regarding routine
introduction of an oral cholera vaccine from a socioeconomic and behavioural perspective as part of a long-term development
for a sustained cholera prevention strategy.
Methods and design: Qualitative and quantitative methods of health social science research will be applied on four
stakeholder levels before and after the mass vaccination campaign. Rapid assessment individual interviews and focus groups will
be used to describe cholera- and vaccine-related views of policy makers, health care professionals and community
representatives. The cultural epidemiological approach will be employed on the individual household resident level in a repeated
cross-sectional design to estimate determinants of anticipated and actual oral cholera vaccine acceptance.
Discussion:  The study presented here is designed to inform about people's perceptions regarding cholera and about
socioeconomic and behavioural factors determining anticipated and actual oral cholera vaccine acceptance in Zanzibar. Its pre-
and post-intervention design using a mixed-methods approach on different stakeholder levels in communities at high risk of
cholera outbreaks will ensure the collection of locally valid data relevant for public health action and planning.
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Background
Etiology, symptoms and treatment of cholera
Cholera is an intestinal disease caused by the bacterium
Vibrio cholerae which spreads mainly through faecal con-
tamination of water and food by infected individuals [1].
Eating raw or undercooked seafood can also cause the
infection since V. cholerae was found on phyto- and zoo-
plankton in marine, estuarine and riverine environments
independent of infected human beings [2,3]. Two out of
ca. 240 serogroups of V. cholerae – O1 and O139 – are
pathogenic. The O1 serogroup can further be subdivided
into two biotypes – classical and El Tor.
After an incubation period of 18 hours to five days,
infected individuals will develop acute watery diarrhoea.
Large volumes of rice-water-like stool and concurrent loss
of electrolytes can lead to severe dehydration and eventu-
ally death if patients are not rapidly treated. Most of the
infected individuals, however, are asymptomatic or suffer
only from mild diarrhoea. An inoculum of 108 bacteria is
needed in healthy individuals to cause severe acute watery
diarrhoea while a 1,000-fold lower dose is sufficient to
cause the disease when gastric acid production is reduced.
Other clinical features besides profuse diarrhoea (more
than three loose stools per day) to establish a cholera
diagnosis include abdominal and muscle cramps and fre-
quent vomiting [4]. Without treatment the case-fatality
rate (CFR) can reach 50% [1].
Treatment of cases depends on the severity and includes i)
giving oral rehydration solutions (ORS) after each stool if
no dehydration is apparent, ii) giving ORS in larger
amounts if moderate dehydration is apparent, and iii)
using intravenous drips of Ringer Lactate or saline for
severely dehydrated patients [4]. Antibiotics can be
administered to shorten the episode in severe cases.
Prevention of cholera
Cholera usually occurs in epidemics and can cause major
disruptions in affected health systems as rigorous meas-
ures have to be taken and patients treated in camps under
quarantine-like conditions. Outbreaks of cholera can eas-
ily be prevented by providing safe water, sanitation and
promoting good personal hygiene behaviour and safe
food handling. Regions where such control measures have
not been realised, or where maintenance and monitoring
of existing schemes is not guaranteed, are at greatest risk
of epidemics and consequently could become endemic
with cholera.
The World Health Organization (WHO) has recently
started to consider the use of vaccines as an additional
public health tool to control cholera in low-income coun-
tries since the implementation of the above-mentioned
prevention and control measures has not had the desired
impact on cholera incidence [5]. Currently only one safe
and efficacious vaccine is available on the market – Duko-
ral® – an oral cholera vaccine (OCV) consisting of killed
whole-cell V. cholerae O1 with purified recombinant B-
subunit of cholera toxoid. It has to be administered in two
doses about one week apart. It confers, as shown in field
trials in Bangladesh, Peru and Mozambique, 60–85% pro-
tection for six months in young children and about 60%
in older children and adults after two years [6-8]. Longini
Jr. et al. [9] used data collected in 1985–1989 from a ran-
domised controlled OCV trial in Bangladesh to calculate
reductions of cholera cases. Their model indicated that a
50% coverage with OCV would lead to a 93% reduction
in the entire population while a lower coverage of 30%
would still reduce the cholera incidence by 76%.
Global and local burden of cholera
Cholera is mainly endemic in low-income countries in
Africa, Asia, Central and South America. A total of
177,963 cases and 4,031 deaths, corresponding to a CFR
of 2.3%, have been reported to WHO in 2007 with Africa
having the largest share of worldwide reported cholera
cases (94%) and deaths (99%) [10]. This share of offi-
cially reported cases from Africa has increased considera-
bly from 20% in the 1970s to 94% in the period 2000–
2005 while the Asian share has simultaneously dropped
from 80% to 5.2% over the same three decades [11]. There
is a similar picture with regard to reported deaths: Africa's
share has increased from 22% to 97%, and Asia's has
showed a steep decline from 77% to 2.4%. It has to be
noted, however, that these official figures do not reflect
the true burden of cholera since serious under-reporting
due to technical (surveillance system limitations, prob-
lems with case definition and lack of standard vocabu-
lary) and political (fear of travel or trade sanctions)
reasons are suspected [10]. Zuckerman et al. [12] identi-
fied mainly under-reporting from the Indian subconti-
nent and Southeast Asia in a review carried out in 2004.
In Zanzibar, where this study will be conducted, a cholera
outbreak with 411 cases and 51 deaths was reported for
the first time in 1978 from a fishermen village [13]. Thir-
teen outbreaks followed since then with almost annual
episodes since the year 2000, with case-fatality rates rang-
ing from 0% to 17% and showing a downward trend over
the last two decades (Reyburn et al., unpublished data).
During the last outbreaks in 2006/2007, 3,234 cases and
62 deaths were reported (CFR: 1.9%). A seasonal pattern
can be observed that follows the rainy seasons (usually
from March to June and from October to November) dur-
ing which widespread flooding occurs frequently. Such
deteriorating environmental conditions subsequently
expose the majority of inhabitants on both islands to an
increased risk of water-borne diseases due to the scarcity
of safe drinking water supplies and a generally poor or
lacking sanitation infrastructure in periurban and rural
areas.BMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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Despite all efforts in the past and the inexpensive and rel-
atively easy use of ORS as major treatment [14], cholera
still poses a serious public health problem in low-income
countries. Thus, a concerted action is needed to control
cholera and to mitigate its health-related and economic
consequences not only by maintaining and improving
existing measures like water supply, sanitation and
hygiene behaviour but also by assessing new prevention
options like OCV mass vaccinations of vulnerable popu-
lations [5,12,15].
Importance of sociocultural and behavioural research on 
vaccine introduction
Public health interventions to reduce disease burden must
take into account the local realities to achieve a sustaina-
ble benefit for the affected populations. Solely relying on
prevention or treatment measures that proved to be suita-
ble in a given context does not necessarily make it appro-
priate for other situations.
Vaccination programmes have suffered a reduced cover-
age (e.g. rumours about tetanus toxoid causing infertility
in Tanzania [16]) or were even brought to a halt because
of an ignorance of local realities (e.g. Northern Nigerian
resistance to polio vaccination [17,18]). Other interven-
tions, especially when implemented in a top-down
approach, experienced the same difficulties [19-21].
To ensure the success of vaccination campaigns, a vaccine
should not only be efficacious, relatively trouble-free for
patients in its administration and preferably also cost-
effective, but it is equally important that implementers
consider community-held ideas, fears and individual
help-seeking behaviour regarding the infectious disease
and the vaccine of interest [22,23].
Infrastructure, logistics, politics, and social and cultural
features were identified as significant factors which deter-
mine vaccine acceptance and thus the success or failure of
immunisation programmes in low-income countries [24-
26]. The importance of the social and cultural context on
vaccine acceptance was assessed in various recent studies
for typhoid fever and shigellosis (e.g. in Asian countries
[27-31]). It was reasserted that the importance of the
social and cultural context on vaccine introduction has to
be studied carefully in order to improve vaccination cov-
erage [32].
Research to improve the health of people needs to include
gender issues since they play a crucial role in health and
health planning [33]. Gender differences are context-spe-
cific and thus require that sociocultural and behavioural
research be done to complement clinical or epidemiolog-
ical research. A recent review on the control of tropical dis-
eases concluded that more detailed data about illness
experience, meaning and help-seeking behaviour is
needed on the gender level to inform the planning and
execution of health interventions [34].
Socioeconomic features, and cultural beliefs and prac-
tices, may vary across and within different sites or popula-
tions. And since differences in income, education,
neighbourhood, infrastructure, etc. can affect people's
health and behaviour regarding risk and relief, it is pru-
dent to include site-specific analyses when doing research
on the acceptance of community vaccine interventions.
Protocol review and ethical clearance
This paper summarises the protocol that had been
reviewed by two independent scientists with expertise in
the field of cholera and social science research before it
was submitted to and accepted by the WHO Research Eth-
ics Review Committee and the Ethics Committee of Zan-
zibar.
All participants will be informed about the study and indi-
vidual written consent obtained before conducting discus-
sions or interviews. All data will be handled with strict
confidentiality and made anonymous before analysis.
Rationale for research: socioeconomic and behavioural 
(SEB) study
In late 2006, WHO received a grant from the Bill and
Melinda Gates Foundation to work on the pre-emptive
use of OCV in vulnerable populations at risk. The main
focus of this grant is to examine how OCV can sustainably
be used in countries with endemic cholera in addition to
usually recommended control measures such as provision
of safe water, adequate sanitation and health education.
An important feature of the project is to collect evidence
to assess the usefulness and financial stability of establish-
ing an OCV stockpile.
To achieve these goals, WHO launched a joint venture
with the Ministry of Health and Social Welfare of Zanzibar
(MoHSW) to vaccinate 50,000 community residents older
than two years living in communities at high risk of chol-
era with Dukoral®. The two islands of Zanzibar (Figure 1)
were chosen as study area since they have been regularly
affected by cholera over the past three decades and since
the local government wishes to enhance its strategy to
control the disease and to examine the possibility of intro-
ducing OCV as a public health measure.
Complementary to the vaccination campaign, since no
sociocultural and behavioural studies related to cholera
and OCV introduction have been conducted yet in African
settings, the SEB study was conceived as a pilot project to
address the research questions stated below. Besides the
focus on cholera, it was also decided to include, to a lesser
extent, shigellosis (bloody dysentery caused by Shigella
spp.) in this research to investigate similarities and differ-BMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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ences between the community perceptions of these two
serious and potentially fatal diarrhoeal diseases.
Aims and research questions
The main aim of the SEB study, its stakeholders and
research questions are as follows:
To generate evidence on the role socioeconomic and soci-
ocultural factors can play to inform government policies
regarding the introduction of OCV as part of a sustainable
and financially viable cholera control strategy.
To inform the Government of Zanzibar, in particular the
Ministry of Health and Social Welfare, regarding the
national policy on cholera control and the use of OCV on
the archipelago.
Stakeholders
Research will be done on the following four stakeholder
levels in Zanzibar:
- Level I: policy makers on national and regional level
- Level II: allopathic and traditional health care providers
working in the target areas and district hospitals
- Level III: formal and informal local government and
community leaders and teachers from the target areas
- Level IV: adult community residents (household level)
Research questions
In populations where cholera is endemic:
- What are the perceptions of cholera in the context of
diarrhoeal diseases, in particular shigellosis?
- What are the essential features of cholera and shigellosis?
- What is the acceptance of OCV?
For each question, the following comparisons will be
made between:
- Gender
- Site: periurban (Unguja) vs. rural (Pemba)
- Vaccination (intervention) status
- Stakeholders: all four levels
Methods and design
Study setting
Zanzibar consists of two major islands, Unguja (also
named Zanzibar) and Pemba. They are situated in the
Indian Ocean about 40–60 km off the coast of Tanzania
and a few degrees south of the equator (Figure 1). In 1964,
shortly after independence from the colonial powers, the
archipelago and Tanganyika formed the United Republic
of Tanzania. Zanzibar as a semiautonomous entity within
Tanzania consists of five regions which are subdivided
into ten districts, 50 constituencies and 296 communities
(Shehias). The main islands cover approximately 2,557
km2 (Unguja: 1,651 km2, Pemba 906 km2). They are
inhabited by a population of approximately 985,000 (in
2002) with Unguja having a share of 63% and Pemba of
37%. The inter-censal annual growth rates (1988–2002)
varied from 2.1 to 4.5% [35]. Its mainly Islamic inhabit-
ants are speaking Kiswahili. One-fourth of the population
has not received any education and the primary education
net enrolment ratio amounts to 77% [36].
The majority of the population (71%) is having access to
piped water while a minority has to rely on drinking water
from wells (27%) and other sources like street vendors,
rainwater, spring water, and open water courses (2%)
[36]. About half of the population (53%) has access to pit
latrines, while more than one-fourth has no toilet facility
(28%) and 12% – mainly in urban areas – are using a
flush toilet.
The top three causes of admission to Zanzibar hospitals in
2007 were malaria (27.4% of all admissions), gastroen-
teritis (12.7%) and pneumonia (9.9%) [37]. The main
causes of death were malaria (18.4%), hypertension
(8.5%) and pneumonia (7.9%) with gastroenteritis rank-
ing on fourth place (7.5%). The main sources of help con-
sulted are primary health care units which are situated
within four kilometres of households for over 90% of the
population. Monthly mean per capita expenditure was
TZS21,000 (ca. USD18) in 2004/5 with a 2.1% share for
health-related expenditures [36]. Life expectancy at birth
has risen from 47 years in 1988 to 57 years in 2002 [35].
Target areas
The SEB study will take place in the periurban Shehia of
Chumbuni (population estimate: ca. 13,500) in Unguja
and the rural Shehia of Mwambe (population estimate:
ca. 8,500) in Pemba. These two Shehias represent core
areas of the mass vaccination campaign and were selected
based on epidemiological data collected from recent chol-
era outbreaks (Reyburn et al., unpublished data) [13]. The
selection of Chumbuni and Mwambe as target areas for
the SEB study was therefore based on epidemiological vul-
nerability criteria (i.e. attack rates) and not on socioeco-
nomic status.
Methodological framework
The research questions will be answered by using both
quantitative and qualitative methods suited for the differ-
ent stakeholder levels. On levels I to III rapid assessmentBMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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Map of Zanzibar with the two main islands Figure 1
Map of Zanzibar with the two main islands. Courtesy of the University of Texas Libraries. The University of Texas at 
Austin.BMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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methods will be used [38,39] while on level IV the cul-
tural epidemiological approach using Explanatory Model
Interview Catalogue (EMIC) interviews will be employed
[40]. Focus group discussions (FGD) will also be con-
ducted as preparation for EMIC interviews.
Level I to III: rapid assessments
Rapid assessments have been utilised to address various
health issues including malaria, sexually transmitted dis-
eases, diarrhoeal disease, water and sanitation, and nutri-
tion to name a few. Rapid assessments are
methodologically tied to the basic tenets of anthropolog-
ical ethnographic research which emphasises the use of
multiple sources of data to gain various perspectives on
social phenomena.
The rapid assessments in this study will provide the mean-
ings and experiences of how community leaders, health
care providers and policy makers perceive the importance
of cholera as a public health concern and the need and
demand for a cholera vaccine. These data will be impor-
tant for future public health implementation of an oral
cholera vaccination programme.
Level IV: cultural epidemiology
Cultural epidemiology incorporates qualitative and quan-
titative methods of health research and uses culturally
adapted EMIC interviews to elicit locally valid representa-
tions of illness-related experience, meaning and behav-
iour [41]. Like classical epidemiology, cultural
epidemiological research can focus on descriptive, analyt-
ical or comparative questions with regard to control of a
disease or other public health interests. Analytical studies
in cultural epidemiology consider the impact local catego-
ries of distress, perceived causes and help seeking – similar
to the epidemiological risk factors – are having on clinical
or public health outcomes.
A first concept of this research approach was already pro-
posed 20 years ago to the benefit of health planning
within the context of diarrhoeal illnesses and ORS promo-
tion [42]. An early validation of this approach was later
done in central Thailand when EMIC interviews were used
to describe local diarrhoeal illnesses for generating public
health policy recommendations [43]. In this study, EMIC
interviews will be used to describe the cultural epidemiol-
ogy of cholera and shigellosis and to estimate determi-
nants of OCV acceptance.
A repeated cross-sectional cultural epidemiological study
will be conducted in the two target areas (Figure 2). After
a preparatory phase, where focus group discussions will
be held, a baseline survey using EMIC interviews (phase
1) will be done in a random sample from each Shehia.
After the intervention new samples will be drawn ran-
domly based on the vaccination status. The same instru-
ment will then be used again but with minor changes to
account for the post-intervention status of the communi-
ties (phase 2).
Focus group discussions
Focus group discussions will be used to describe the con-
text of cholera and shigellosis in the target areas. Results
from the FGD among community residents will help to
guide the planned quantitative research, i.e. the FGD
guideline follows the topics and items that will be elicited
in the EMIC interviews described below.
EMIC interviews
The interview will enquire about the sociocultural context
in terms of illness-related experience, meaning and help-
seeking behaviour and about topics related to vaccination.
Under experience, different aspects of the illness like phys-
ical symptoms and psycho-emotional and social prob-
lems and also financial issues that can have an impact on
patients will be elicited. Under meaning, respondents will
be questioned about their views and opinions on why and
how they think one can get the illness with regard to vari-
ous categories of perceived causes including biological,
behaviour-related, social and traditional/magico-religious
factors. To find out more about sources of help seeking,
respondents will be asked to identify and assess all health
care providers, i.e. locally available allopathic and tradi-
tional sources, patients suffering from cholera or shigello-
sis will likely consult. The possible options for self-
treatment (at home, not at a health-care provider) will
also be elicited.
Variables to be elicited will include:
- Sociodemographic factors
- Categories of diarrhoeal illnesses, name of condition
- Perceived severity of cholera and shigellosis episodes
- Perceived vulnerability of cholera and shigellosis
- Illness experience: operationalised as patterns of distress
(PD) related to cholera and shigellosis
- Illness meaning: operationalised as perceived causes
(PC) related to cholera and shigellosis
- Illness behaviour: operationalised as help seeking (HS)
within and outside the household related to cholera and
shigellosis
- Stigma (index) of cholera
- Prior episodes of choleraBMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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- Prevention of cholera
- Experience and perception of vaccinations
- Barriers to vaccination (only phase 2)
- Anticipated vaccination status (only phase 1)
- Willingness-to-pay for OCV
- Actual vaccination status, i.e. vaccinated/unvaccinated,
not to be elicited but recorded during vaccination cam-
paign
Sample size calculation for EMIC interviews
The following calculations are based on a 95% signifi-
cance level and 80% power. The prominence means of the
different categories of cultural epidemiological variables
will be compared in bivariate analyses (by site, gender,
anticipated vs. actual vaccination status) and tested for
significant differences using the Wilcoxon rank-sum test.
To detect a difference of 0.5 between prominence means
with equal standard deviations of 1.5, a sample size of
164 for each group is required. The calculation is based on
a two-sample t-test assuming a worst-case scenario, i.e. no
underlying distribution in the data, which requires that
the sample size derived from the t-test (n = 142) be
divided by 0.864 which equals 164.4 [44]. Hence, the
Outline of the repeated cross-sectional design for household-level study Figure 2
Outline of the repeated cross-sectional design for household-level study. Not shown is the preparatory phase taking 
place before phase 1. F: Female, M: Male.
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overall sample size (two groups per phase times two
phases) will be 656, with a sample size of 328 per phase.
Data collection
Level I to III
Strategy
Rapid assessment individual interviews and focus groups
will collect qualitative information on policy makers' con-
siderations and need for information for planning the
introduction of a cholera vaccination programme. This
phase of the study will also involve data collection with
health care providers and community leaders on their per-
ceptions of cholera, its importance to community resi-
dents, and their interest in the OCV. This research will
explore policy issues and processes, as well as barriers and
enabling factors that are likely influences in the introduc-
tion of a vaccine against cholera. The descriptive data of
the rapid assessment interviews and focus groups can be
related to and compared with level IV data. The approxi-
mate duration of this phase of the study is four weeks. It
will be conducted following the mass OCV campaign in
order to ground perspectives on the acceptance of an OCV
in real world contexts and experiences.
Instrument
In-depth interviews and group discussions are open-
ended and semi-structured to both cover critical topics
and allow the respondents to identify and discuss what is
important to them regarding cholera and the use of a
cholera vaccine. For each stakeholder level specific inter-
view and discussion guidelines have been created, trans-
lated and orally back-translated to ensure their
intelligibility and appropriateness. Two experienced field
researchers will conduct the research either in English or
Kiswahili depending on the respondents. Each session
will last approximately one hour.
Sampling
The following groups will be selected purposively:
- Policy makers (n = 10–20) including national and
regional policy makers (e.g. from MoHSW, international
non-governmental organisations);
- Allopathic and traditional health care providers (n = 6–
8 per island) working in the target areas and district hos-
pitals;
- Formal and informal local government and community
leaders and teachers (n = 6–8 per island) from the target
areas (e.g. Shehas, secular and Islamic teachers).
Level IV: preparatory phase
Strategy
Community residents will be approached on both islands
and information collected in focus group discussions.
Data will be collected to complete or expand the lists of
variables of the different EMIC interview sections men-
tioned above. The approximate duration of this phase is
two weeks with one team working per site. This phase
must be completed before phase 1 starts.
Instrument
A FGD guideline was drafted which covers all the relevant
issues of the EMIC interviews. Each team will consist of a
moderator and a note taker.
Sampling
- Sample: adults (≥ 18 years) from both communities;
- Sampling frame: registers from Shehias adjacent to the
target Shehias;
- Sampling method: stratified purposive sample, by gen-
der and age group (18–45 years, >45 years);
- Exclusion criteria: belonging to other stakeholder level I
to III;
- Sample size: n = 48–64, eight FGD with each having ca.
6–8 respondents (4 FGD per site)
Level IV: phase 1 (pre-vaccination)
Strategy
Community residents will be approached on both islands
and information collected through EMIC interviews. Data
will be collected i) to clarify the local features of cholera
and shigellosis; and ii) to identify social and cultural
determinants of anticipated OCV acceptance. The approx-
imate duration of this phase is about ten weeks. Three
teams each per site will be working simultaneously. This
phase must be completed before the social mobilisation
and vaccination campaign starts.
Instrument
An EMIC interview for phase 1 was drafted and, once it
has incorporated information from the preparatory phase
(FGD), will be pilot tested and finalised before imple-
mentation. Since the general adult population – and not
cases – will be interviewed, it was decided to introduce the
topic to the interviewees by using slightly varying gender-
specific vignettes which describe cardinal physical symp-
toms of cholera and shigellosis. This approach ensures
that the interviewees will respond with regard to the clin-
ically relevant conditions and not with regard to local
notions of diarrhoeal illnesses labelled by the respective
local terms for cholera and shigellosis.
A ten-day workshop will be conducted to train the field-
workers in interview and data entry skills, to familiarise
them with the instrument and to pilot it under field con-
ditions. Each team will consist of an interviewer and aBMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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note taker. Narrative data will be translated and typed on
a daily basis by the teams.
Sampling
- Sample: adults (≥ 18 years) from both target areas;
- Sampling frame: census and Geographic Information
System databases;
- Sampling method: stratified random sample with gender
ratio 1:1;
- Exclusion criteria: belonging to stakeholder level I to III;
- Sample size: n = 164 per site, n = 328 per phase
Level IV: phase 2 (post-vaccination)
Strategy
Community residents will be approached on both islands
and information collected through EMIC interviews. Data
will be collected i) to clarify the local features of cholera
and shigellosis after vaccination, ii) to compare these fea-
tures with pre-vaccination data, iii) to identify social and
cultural determinants of actual OCV acceptance, and iv)
to identify barriers to vaccination. The approximate dura-
tion of this phase is about ten weeks. Three teams each per
site will be working simultaneously. This phase will be
implemented after the end of the vaccination campaign.
Instrument
The EMIC interview will be exactly the same as in phase 1
except that a special section will enquire about the experi-
ence with the vaccination campaign and reasons against
getting vaccinated among both unvaccinated and vacci-
nated respondents.
The interview teams will attend a second week-long work-
shop where they can refresh their skills and where the new
section of the interview will be explained. A second pilot
testing phase will take place to adapt the instrument with
regard to the new section.
Sampling
- Sample: adults (≥ 18 years) from the target areas;
- Sampling frame: vaccination campaign data (vaccinated
people), census database after exclusion of vaccinated
people (unvaccinated people);
- Sampling method: equally stratified random sample among
confirmed vaccinated (two doses of OCV) and unvaccinated
(one to two doses) people with gender ratio 1:1;
- Exclusion criteria: belonging to stakeholder level I to III,
already interviewed in phase 1, member of household
already interviewed;
- Sample size: n = 164 per site, n = 328 per phase
Data management and analysis
Level I to III: rapid assessment data
The rapid assessment interviews and focus group discus-
sions will generate lengthy textual material which will be
tape-recorded, followed by transcription and translation.
This information will be organised and analysed using the
qualitative analysis software of Ethnograph 6.0. This pro-
gramme will allow the data to be multiply coded, seg-
mented and searched according to important and
emerging variables and themes.
Level IV: qualitative data
Information from focus group discussions will be tape-
recorded, followed by transcription and translation. Nar-
ratives from EMIC interviews will be transcribed verbatim
and translated. Typing will be done in a word processor
software while MAXQDA 2007 will be used for managing
the textual data and to facilitate analysis regarding find-
ings from quantitative data.
Level IV: quantitative data
Information will be double-entered and cleaned in Epi
Info 3.4.3 software. Descriptive statistics and bi- and mul-
tivariate analyses will be computed with the statistical
analysis programme Stata 10.
Regarding the cholera vignette, the variables related to ill-
ness experience (PD), meaning (PC) and help-seeking
behaviour (HS) will be coded with a value of two after a
spontaneous response, a value of one after a probed
response and a value of zero for no response at all to
reflect the response style. A value of three will be assigned
to the summary variables (i.e. most troubling, most
important and most useful). For each category of such a
variable, a total prominence will be computed, ranging
from zero to five. Thematically similar individual catego-
ries will be grouped under specific headings (e.g. "physi-
cal symptoms" among PD variables) to enable the
analysis of broader concepts of experience, meaning and
behaviour. Grouped frequencies will be computed by
adding the maximum value based on the response style of
each respondent for every single category falling under
each group. Calculation of the grouped prominence will
follow the same procedure as with the individual varia-
bles.
For questions related to the shigellosis vignette, only fre-
quencies of the categories mentioned in relation to illness
experience, meaning and help-seeking behaviour will be
computed.
Tabulations of the above-mentioned variables will be done
after each phase followed by descriptive, bivariate and mul-
tivariate analyses to address the research questions.BMC Public Health 2009, 9:99 http://www.biomedcentral.com/1471-2458/9/99
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To test for significant differences (p ≤ 0.05) between two
groups, the t-test will be used for normal data and the Wil-
coxon rank-sum test for nonparametric data. The Kruskal
Wallis test will be used for comparing more than two
groups of a nonparametric variable. The Chi2 test and the
Fisher's exact test will be applied for comparing two pro-
portions. To compare paired data, i.e. variables between
cholera and shigellosis vignettes, the McNemar's Chi2 test,
the paired t-test and the paired Wilcoxon test will be used.
Determinants of anticipated and actual OCV acceptance
(outcome variables) will be identified in a twofold
approach. First, bivariate tests (see above) will be done to
see which variables are related with the outcome varia-
bles. Then, variables having a suggestive bivariate rela-
tionship (p ≤ 0.3) with the outcome variables will be
retained as potential explanatory variables for computing
stepwise logistic regression models.
Narrative accounts will be used to clarify and substantiate
the relationships identified in the above analyses.
Data safety and storage
A password-secured data management system will be
established where the responsible researchers on both
islands can up- and download qualitative and quantita-
tive data. Electronic data can only be accessed with per-
mission from the co-investigator(s). Raw data (filled-in
forms, narratives) will be kept under appropriate climatic
and safety conditions in the Public Health Laboratory,
Pemba. The data will be destroyed two years after the
completion of the study (hard copies by incineration and
soft copies by digital erasure).
Translation of instruments and informed consent forms
The English versions of all the instruments and informed
consent forms will go through cultural adaptation and
translation into Kiswahili. Back-translation into English
will ensure the validity of the translation and that no eth-
ical alternation is introduced in the informed consent
forms.
Discussion
The study will clarify local perceptions of cholera and
show how these and socioeconomic factors affect antici-
pated and actual acceptance of oral cholera vaccine in
Zanzibar. The cross-sectional design and mixed-methods
approach, attentive to the interests of various stakehold-
ers, will help to explain critical practical features of chol-
era control. Cultural factors are widely regarded as
important determinants of vaccine acceptance, but diffi-
cult to study. This study has formulated an approach that
enables systematic consideration of their influence. Our
findings and experience will guide the programme in Zan-
zibar. They will also show how research may enhance the
effectiveness of interventions for cholera and other health
problems in various settings where sociocultural and soci-
oeconomic factors influencing population behaviour
require careful study.
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